apremilast (Otezla®)

Policy #  00436  
Original Effective Date:  07/16/2014  
Current Effective Date:  01/01/2018  

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Psoriatic Arthritis
Based on review of available data, the Company may consider the use of apremilast (Otezla®) for the treatment of adult patients with active psoriatic arthritis to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility for apremilast (Otezla) will be considered when all of the following criteria are met:
• Patient has a diagnosis of active psoriatic arthritis; AND
• Patient is 18 years of age or older; AND
• Otezla is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as adalimumab (Humira®) OR etanercept (Enbrel®) OR other drugs such as tofacitinib (Xeljanz/XR®); AND
• Patient has failed treatment with ONE of the following after at least TWO months of therapy: etanercept (Enbrel®), adalimumab (Humira®), ustekinumab (Stelara®), or secukinumab (Cosentyx®) unless there is clinical evidence or patient history that suggests the use of these products will be ineffective or cause an adverse reaction to the patient; AND (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).
• Patient has failed treatment with one or more DMARDs. (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)

Plaque Psoriasis
Based on review of available data, the Company may consider the use of apremilast (Otezla) for the treatment of patients with plaque psoriasis to be eligible for coverage.
• Patient has a diagnosis of moderate to severe plaque psoriasis; AND
• Patient is a candidate for phototherapy or systemic therapy; AND
• Otezla is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as adalimumab (Humira) or etanercept (Enbrel) OR other drugs such as tofacitinib (Xeljanz/XR); AND
apremilast (Otezla®)

Policy # 00436
Original Effective Date: 07/16/2014
Current Effective Date: 01/01/2018

- Patient has greater than 10% of body surface area (BSA) or less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia); AND
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).
- Patient has failed to respond to an adequate trial of one of the following treatment modalities:
  o Ultraviolet B; or
  o Psoralen positive Ultraviolet A; or
  o Systemic therapy (i.e. methotrexate, cyclosporine, acitretin).
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of apremilast (Otezla) when patient selection criteria are not met to be investigational* (with the exception of those denoted above as not medically necessary**).

Based on review of available data, the Company considers the use of apremilast (Otezla) for indications other than those listed above to be investigational.*

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of apremilast (Otezla) when any of the following criteria for the respective disease listed below (and denoted in the patient selection criteria above) are not met to be not medically necessary**:

- For psoriatic arthritis:
  o Patient has failed treatment with one or more DMARDs
  o Patient has failed treatment with ONE of the following after at least TWO months of therapy: etanercept (Enbrel), adalimumab (Humira), ustekinumab (Stelara), or secukinumab (Cosentyx)
- For plaque psoriasis:
  o Patient has greater than 10% of body surface area (BSA) or less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia)
  o Patient has failed to respond to an adequate trial of one of the following treatment modalities:
    - Ultraviolet B; or
    - Psoralen positive Ultraviolet A; or
    - Systemic therapy (i.e. methotrexate, cyclosporine, acitretin).
Background/Overview

Otezla is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP) and is indicated for the treatment of adult patients with active psoriatic arthritis (PsA) as well as the treatment of patients with moderate to severe plaque psoriasis. The inhibition of PDE4 results in increased intracellular cAMP. The mechanism by which Otezla works is not well defined. Otezla is provided as 10mg, 20mg, and 30mg tablets. In order to reduce the risk of gastrointestinal symptoms, the dose should be titrated up to 30mg twice daily. The titration schedule can be found in the prescribing information. Patients with severe renal impairment should be dosed at 30mg once daily.

Psoriatic Arthritis

Psoriatic arthritis is an arthritis that is often associated with psoriasis of the skin. Typically first line treatments such as DMARDs (disease modifying anti-rheumatic drugs) are used to treat this condition.

Plaque Psoriasis

Psoriasis is a common skin condition that is caused by an increase in production of skin cells. It is characterized by frequent episodes of redness, itching and thick, dry silvery scales on the skin. It is most commonly seen on the trunk, elbows, knees, scalp, skin folds and fingernails. This condition can appear suddenly or gradually and may affect people of any age; it most commonly begins between the ages of 15 and 35. Psoriasis is not contagious. It is an inherited disorder related to an inflammatory response in which the immune system produces too much TNF-alpha. It may be severe in immunosuppressed people or those who have other autoimmune disorders such as rheumatoid arthritis. Treatment is focused on control of the symptoms and prevention of secondary infections. Lesions that cover all or most of the body may be acutely painful and require hospitalization. The body loses vast quantities of fluid and becomes susceptible to severe secondary infections that can involve internal organs and even progress to septic shock. Typical treatments for severe cases of plaque psoriasis include ultraviolet therapy or systemic therapies such as MTX or cyclosporine. Newer biologic therapies are also approved for the treatment of plaque psoriasis.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Disease-modifying anti-rheumatic drugs are used for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and lupus. These drugs slow the disease process by modifying the immune system.

- Methotrexate
- Cyclosporine
- Sulfasalazine
- Mercaptopurine
- Gold Compounds

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Otezla was approved in March of 2014 by the FDA for the treatment of adult patients with active psoriatic arthritis. In September of 2014, Otezla gained approval for the treatment of moderate to severe plaque psoriasis in patients that are candidates for phototherapy or systemic therapy.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The safety and efficacy of Otezla in patients with psoriatic arthritis was evaluated in 3 multi-center, randomized, double-blind, placebo-controlled trials of similar design. A total of 1493 adult patients with active psoriatic arthritis despite prior or current treatment with DMARD therapy were randomized. The primary endpoint was the percentage of patients achieving American College of Rheumatology (ACR) 20 responses at week 16. The proportion of patients achieving ACR 20 at week 16 in the placebo group in the three psoriatic arthritis trials was: 19%, 19%, and 18%, respectively. The proportion of patients achieving ACR 20 in the Otezla treatment group in the three psoriatic arthritis trials was 38%, 32%, and 41%, respectively (all of which reached statistical significance p<0.05).

The safety and efficacy of Otezla for plaque psoriasis was studied in two multicenter, randomized, double-blind, placebo-controlled trials (Studies PSOR-1 and PSOR-2) and enrolled a total of 1257 subjects 18 years of age and older with moderate to severe plaque psoriasis [body surface area (BSA) involvement of arthritis trials was: 19%, 19%. Assessment (sPGA) of of t (sPGA) of r with moderate to severe plaque psoriasis [body surface area (BSA) involvement of h热情 disorder or systemic therapy]. Study PSOR-1 enrolled 844 subjects and Study PSOR-2 enrolled 413 subjects. In both studies, subjects were randomized 2:1 to Otezla 30 mg BID or placebo for 16 weeks. Both studies assessed the proportion of subjects who achieved PASI-75 at Week 16 and the proportion of subjects who achieved a sPGA score of clear (0) or almost clear (1) at Week 16. Across both studies, subjects ranged in age from 18 to 83 years, with an overall median age of 46 years. The mean baseline BSA involvement was 25.19% (median 21.0%), the mean baseline PASI score was 19.07 (median 16.80), and the proportion of subjects with sPGA score of 3 (moderate) and 4 (severe) at baseline were 70.0% and 29.8%, respectively. Approximately 30% of all subjects had received prior phototherapy and 54% had received prior conventional systemic and/or biologic therapy for the treatment of psoriasis with 37% receiving prior conventional systemic therapy and 30% receiving prior biologic therapy. Approximately one-third of subjects had not received prior phototherapy, conventional systemic nor biologic therapy. A total of 18% of subjects had a history of psoriatic arthritis. In PSOR-1, 5.3% of subjects in the placebo group achieved PASI-75 vs. 33.1% in the Otezla group. In the placebo group, there were 3.9% of patients that achieved an sPGA of clear or almost clear vs. 21.7% in the Otezla group. In PSOR-2, 5.8% of subjects in the placebo group achieved PASI-75 vs. 28.8% in the Otezla group. In the placebo group, there were 4.4% of patients that achieved an sPGA of clear or almost clear vs. 20.4% in the Otezla group.
apremilast (Otezla®)

Policy #  00436
Original Effective Date:  07/16/2014
Current Effective Date:  01/01/2018

References

Policy History
Original Effective Date:  07/16/2014
Current Effective Date:  01/01/2018
07/10/2014  Medical Policy Committee review
07/16/2014  Medical Policy Implementation Committee approval. New policy.
11/06/2014  Medical Policy Committee review
11/21/2014  Medical Policy Implementation Committee approval. Added a new indication for plaque psoriasis and made updates throughout to reflect the new indication (background, rationale, etc).
10/29/2015  Medical Policy Committee review
11/16/2015  Medical Policy Implementation Committee approval. No change to coverage eligibility.
11/03/2016  Medical Policy Committee review
11/16/2016  Medical Policy Implementation Committee approval. No change to coverage eligibility.
12/07/2017  Medical Policy Implementation Committee review
12/20/2017  Medical Policy Implementation Committee approval. Removed requirement for Humira and Enbrel prior to Otezla for plaque psoriasis. Changed to fail one of the following for psoriatic arthritis: Humira, Enbrel, Stelara, or Cosentyx.

Next Scheduled Review Date:  12/2018

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:
   A.  Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
   B.  Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
      1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
      2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
      3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
   A.  In accordance with nationally accepted standards of medical practice;
   B.  Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
   C.  Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
apremilast (Otezla®)

Policy #    00436
Original Effective Date:   07/16/2014
Current Effective Date:  01/01/2018

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.